The Latest
- Sep 23, 2020MedX Health Corp. Bolsters Global Footprint and Adds Renowned Skin Care Expert to Senior Leadership Team
- Sep 09, 2020MedX Health Corp. announces management changes and increased focus on SIAscopy™ on DermSecure™
- Apr 28, 2020Beacon Securities Research April Report On MedX Health Corp.
- Apr 16, 2020MedX Health Corp. Announces Proposed Extension Of Non-brokered Private Placement
- Apr 02, 2020MedX Receives MDSAP Certification
Reports and Filings
- May 23, 2017Interim Financial Statements/Report - English
- May 01, 2017MD&A - English
- May 01, 2017Audited Annual Financial Statements - English
- Nov 28, 2016MD&A - English
- Nov 28, 2016Interim Financial Statements/Report - English
- Aug 26, 2016Interim Financial Statements/Report - English
- May 30, 2016Interim Financial Statements/Report - English
- May 30, 2016MD&A - English
- Apr 29, 2016Audited Annual Financial Statements - English
- Apr 29, 2016MD&A - English
MedX is committed to technology that is safe and effective.
The safety and effectiveness for patients is our first priority. SIAcopy is rapid, patient-friendly, accurate, easy to use, and practice-friendly. SIAscopy has been used for over 12 years and is supported by over 15 published clinical studies and 24 in vivo clinical posters. MedX Health designs, develops and distributes innovative imaging and software technologies that have been tested for safety and effectiveness and have been cleared and licensed for use in Canada, European Union, and Australia.
The technology has gone through stringent testing and it has been cleared for sale by the following regulatory bodies: Health Canada, CE and ARTG.